Universidad de Navarra-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2022

  1. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 670-675

  2. Quality Assessment of a Large Multi-Center Flow Cytometric Dataset of Acute Myeloid Leukemia Patients—A EuroFlow Study

    Cancers, Vol. 14, Núm. 8

2021

  1. Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma

    Cancers, Vol. 13, Núm. 19

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)

    Haematologica, Vol. 102, Núm. 2, pp. 235-245

2016

  1. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases

    Cytometry Part B - Clinical Cytometry, Vol. 90, Núm. 1, pp. 91-100

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

2012

  1. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

2009

  1. Prolonged idiotypic vaccination against follicular lymphoma

    Leukemia and Lymphoma, Vol. 50, Núm. 1, pp. 47-53

2006

  1. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

    Journal of the National Cancer Institute, Vol. 98, Núm. 18, pp. 1292-1301